$HRMY News

Last published 1w ago

1w agoHRMYHarmony Biosciences Third Quarter 2026 Financial Results - HARMONY BIOSCIENCES HOLDINGS INCEarnings Call TranscriptsGood morning. My name is Nikki, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Bioscience's third quarter financial results conference call. All participant lines
1w agoHRMYHarmony Biosciences Holdings, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
1w agoHRMYHarmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class ProfileGlobeNewswireWAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending
3w agoHRMYHarmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswirePLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before
1mo agoHRMYHarmony Biosciences Announces Planned CEO Transition to Support Next Phase of GrowthGlobeNewswireThe Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027. Current
2mo agoHRMYHarmony Biosciences Announces Poster Presentations at the 16th European Epilepsy CongressGlobeNewswirePLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole
2mo agoHRMYHarmony Biosciences to Participate in 2026 Cantor Global Healthcare ConferenceGlobeNewswirePLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor
3mo agoHRMYHarmony Biosciences to Participate in Piper Sandler Virtual CNS SymposiumGlobeNewswirePLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler
3mo agoHRMYHarmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class ProfileGlobeNewswireWAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion
3mo agoHRMYHarmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026GlobeNewswirePLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before
3mo agoHRMYHarmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO TransitionBusiness WireWAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion Full Q2 2026 Financial Results and Business
5mo agoHRMYParagon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva PharmaceuticalBusiness WireAgreement highlights Paragon's ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions Paragon Biosciences today announced the closing
5mo agoHRMYHarmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual MeetingBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the
5mo agoHRMYGoldman Sachs 47th Annual Global Healthcare ConferenceHARMONY BIOSCIENCES HOLDINGS INCEarnings Call TranscriptsAll right. Welcome, everyone. Good morning, and thanks for joining us here at the Goldman Sachs Global Healthcare Conference. We're thrilled to be joined by the team from Harmony Biosciences today, and maybe I will start
5mo agoHRMYHarmony Biosciences to Participate in Upcoming Investor ConferencesBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare
6mo agoHRMYHarmony Biosciences First Quarter 2026 Financial ResultsHARMONY BIOSCIENCES HOLDINGS INCEarnings Call TranscriptsHello, and thank you for standing by. My name is Mel, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Harmony Biosciences first quarter 2026 financial results. All
6mo agoHRMYHarmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic PrioritiesBusiness WireWAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET
6mo agoHRMYHarmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026Business WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a
6mo agoHRMYHarmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual MeetingBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS
7mo agoHRMYHarmony Biosciences Appoints Glenn Reicin as Chief Financial OfficerBusiness WireCOMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer,
7mo agoHRMYHarmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its BoardBusiness WireAppointments support Harmony's next phase of growth and long‑term value creation Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and
7mo agoHRMYHarmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare ConferenceBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual Needham Virtual Healthcare Conference on Monday, April
8mo agoHRMYHarmony Biosciences to Participate in Upcoming Investor ConferencesBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date:
8mo agoHRMYHarmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 BillionBusiness WireWAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward
8mo agoHRMYHarmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric NarcolepsyBusiness WireHarmony Biosciences (NASDAQ:HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of
9mo agoHRMYHarmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026Business WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets.
11mo agoHRMYBeacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEGGlobeNewswireBOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (NASDAQ:HRMY), a
11mo agoHRMYHarmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet SyndromeBusiness WireData presented at the 2025 American Epilepsy Society Annual Meeting Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the presentation of initial open-label extension (OLE) data from the company's
11mo agoHRMYHarmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant FormulationBusiness WireNew Drug Application to be submitted in early 2026; target PDUFA in Q1 2027 Utility patent applications filed with potential exclusivity to 2044 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced
11mo agoHRMYHarmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of HypersomnolenceBusiness WireBP1.15205 is a differentiated chemical scaffold, demonstrating high potency and selectivity in preclinical studies with a favorable safety profile and the potential for once-daily dosing Topline clinical data expected
11mo agoHRMYHarmony Biosciences to Participate in Upcoming Investor ConferencesBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare
1y agoHRMYHarmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865MBusiness WireWAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500 to Achieve 8,100 Average Patients in Q3 2025 Strong Cash
1y agoHRMYHarmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue GuidanceBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3
1y agoHRMYHarmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X SyndromeBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT Study did not
1y agoHRMYHarmony Biosciences Holdings, Inc. (HRMY) Presents at Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
1y agoHRMYHarmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy CongressBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30 – September 3, 2025, at
1y agoHRMYHarmony Biosciences to Participate in 2025 Cantor Global Healthcare ConferenceBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New York, N.Y., on Thursday,
1y agoHRMYHarmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoHRMYHarmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025Business WireWAKIX® (pitolisant) Franchise Continues Strong Growth with Net Revenue of $200.5M for Q2 2025 (+16% YoY Growth); Increases Average Patients by 400 to Achieve 7,600 Average Patients in Q2 2025 Phase 3 RECONNECT
1y agoHRMYHarmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025Business WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a
1y agoHRMYHarmony Biosciences to Participate in H.C. Wainwright "HCW@Home" SeriesBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, July 17, 2025, at 10:00 a.m.
1y agoHRMYHarmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025Business WireBP1.15205 is a potentially best-in-class OX2R agonist being investigated in narcolepsy and other central disorders of hypersomnolence A first-in-human study is planned to start in 2H 2025; topline clinical data is
1y agoHRMYHarmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA LitigationBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin's Abbreviated New Drug Application (ANDA) for a
1y agoHRMYHarmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare ConferenceBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on
1y agoHRMYHarmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance Business WireWAKIX® (pitolisant) Net Revenue of $184.7 Million for First Quarter 2025; Representing 20% Growth Year-over-Year; Reiterates Guidance of $820-$860M Net Income Grew 19% Year-over-Year, Building on Four
1y agoHRMYHarmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025Business WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a
1y agoHRMYHarmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X SyndromeBusiness WireData to be Presented at the Hot Topics in Child Neurology Podium Presentation Session at the American Academy of Neurology Annual Meeting Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the
1y agoHRMYHarmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of DirectorsBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics.
1y agoHRMYHarmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare ConferenceBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday,
1y agoHRMYHarmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio ExpandsBusiness WireHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO,